MX382017B - Metodos para el tratamiento de cancer pancreatico. - Google Patents

Metodos para el tratamiento de cancer pancreatico.

Info

Publication number
MX382017B
MX382017B MX2015008898A MX2015008898A MX382017B MX 382017 B MX382017 B MX 382017B MX 2015008898 A MX2015008898 A MX 2015008898A MX 2015008898 A MX2015008898 A MX 2015008898A MX 382017 B MX382017 B MX 382017B
Authority
MX
Mexico
Prior art keywords
treatment
methods
pancreatic cancer
taxane
gemcitabine
Prior art date
Application number
MX2015008898A
Other languages
English (en)
Other versions
MX2015008898A (es
Inventor
Markus Renschler
Neil P Desai
Original Assignee
Abraxis Bioscience Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51165317&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX382017(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abraxis Bioscience Llc filed Critical Abraxis Bioscience Llc
Publication of MX2015008898A publication Critical patent/MX2015008898A/es
Publication of MX382017B publication Critical patent/MX382017B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5169—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)

Abstract

En la presente se proporcionan métodos para el tratamiento de cáncer pancreático metastásico que comprende la administración de una composición que comprende nanopartículas que comprenden un taxano (por ejemplo, paclitaxel) y una proteína portadora en combinación con gemcitabina.
MX2015008898A 2013-01-11 2014-01-10 Metodos para el tratamiento de cancer pancreatico. MX382017B (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361751820P 2013-01-11 2013-01-11
US201361752355P 2013-01-14 2013-01-14
US13/794,480 US9511046B2 (en) 2013-01-11 2013-03-11 Methods of treating pancreatic cancer
PCT/US2014/011145 WO2014110443A1 (en) 2013-01-11 2014-01-10 Methods of treating pancreatic cancer

Publications (2)

Publication Number Publication Date
MX2015008898A MX2015008898A (es) 2015-10-14
MX382017B true MX382017B (es) 2025-03-11

Family

ID=51165317

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015008898A MX382017B (es) 2013-01-11 2014-01-10 Metodos para el tratamiento de cancer pancreatico.

Country Status (25)

Country Link
US (3) US9511046B2 (es)
EP (1) EP2943192B9 (es)
JP (3) JP6342918B2 (es)
KR (1) KR102205710B1 (es)
CN (2) CN109793728A (es)
AU (1) AU2013203699B2 (es)
BR (1) BR112015016681A8 (es)
CA (1) CA2897589C (es)
CY (1) CY1124273T1 (es)
DK (1) DK2943192T3 (es)
ES (1) ES2878145T3 (es)
HK (1) HK1216853A1 (es)
HR (1) HRP20211062T1 (es)
HU (1) HUE056612T2 (es)
IL (2) IL239739A0 (es)
LT (1) LT2943192T (es)
MX (1) MX382017B (es)
NZ (2) NZ734971A (es)
PL (1) PL2943192T3 (es)
PT (1) PT2943192T (es)
RS (1) RS62076B1 (es)
SI (1) SI2943192T1 (es)
SM (1) SMT202100377T1 (es)
WO (1) WO2014110443A1 (es)
ZA (1) ZA201504877B (es)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1585548B1 (en) 2002-12-09 2018-06-27 Abraxis BioScience, LLC Compositions and methods of delivery of pharmacological agents
WO2006089290A1 (en) 2005-02-18 2006-08-24 Abraxis Bioscience Inc.. Combinations and modes of administration of therapeutic agents and combination therapy
US8735394B2 (en) 2005-02-18 2014-05-27 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
BRPI0615265A8 (pt) 2005-08-31 2018-03-06 Abraxis Bioscience Llc composições compreendendo agentes farmacêuticos pouco hidrossoluíveis e agentes antimicrobianos
PT2117520T (pt) 2006-12-14 2018-12-04 Abraxis Bioscience Llc Terapia do cancro da mama com base no estado do receptor do hormona com nanoparticulas compreendendo taxane
AU2008260447B2 (en) * 2007-06-01 2013-10-10 Abraxis Bioscience, Llc Methods and compositions for treating recurrent cancer
CN102460167B (zh) 2009-04-15 2015-07-22 阿布拉科斯生物科学有限公司 不含朊病毒的纳米颗粒组合物和方法
CN104784121A (zh) 2010-03-26 2015-07-22 阿布拉科斯生物科学有限公司 治疗肝细胞癌的方法
NZ602385A (en) 2010-03-29 2014-08-29 Abraxis Bioscience Llc Methods of treating cancer
WO2011123393A1 (en) 2010-03-29 2011-10-06 Abraxis Bioscience, Llc Methods of enhancing drug delivery and effectiveness of therapeutic agents
KR20130088116A (ko) 2010-06-04 2013-08-07 아브락시스 바이오사이언스, 엘엘씨 췌장암의 치료 방법
MY166014A (en) * 2010-06-07 2018-05-21 Abraxis Bioscience Llc Combination therapy methods for treating proliferative diseases
BR112013027674A2 (pt) 2011-04-28 2016-09-06 Abraxis Bioscience Llc "usos de composições de nanopartículas, composições compreendendo as referidas nanopartículas e cateter com uma agulha".
PT2790675T (pt) 2011-12-14 2019-09-23 Abraxis Bioscience Llc Utilização de excipientes poliméricos para a liofilização ou a congelação de partículas
US9149455B2 (en) 2012-11-09 2015-10-06 Abraxis Bioscience, Llc Methods of treating melanoma
US9511046B2 (en) 2013-01-11 2016-12-06 Abraxis Bioscience, Llc Methods of treating pancreatic cancer
ES2804323T3 (es) 2013-03-12 2021-02-05 Abraxis Bioscience Llc Procedimientos de tratamiento de cáncer de pulmón
CA2903548A1 (en) 2013-03-14 2014-09-25 Abraxis Bioscience, Llc Methods of treating bladder cancer
US10705070B1 (en) 2015-03-05 2020-07-07 Abraxis Bioscience, Llc Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug
US10527604B1 (en) 2015-03-05 2020-01-07 Abraxis Bioscience, Llc Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel
JP6921759B2 (ja) 2015-06-04 2021-08-18 クリティテック・インコーポレイテッド 捕集装置および使用法
EP3313401B1 (en) 2015-06-29 2021-10-06 Abraxis BioScience, LLC Nanoparticles comprising sirolimus and an albumin for use in treating epithelioid cell tumors
US10925852B2 (en) * 2015-06-30 2021-02-23 The Trustees Of Columbia University In The City Of New York Talc-bound compositions and uses thereof
SG10201913409VA (en) 2016-04-04 2020-03-30 Crititech Inc Methods for solid tumor treatment
US20200071415A1 (en) * 2017-03-17 2020-03-05 Imclone Llc Combination therapy for pancreatic cancer
SG11201909840TA (en) 2017-06-09 2019-11-28 Crititech Inc Treatment of epithelial cysts by intracystic injection of antineoplastic particles
CN115919815A (zh) 2017-06-14 2023-04-07 克里蒂泰克公司 治疗肺部疾病的方法
KR20200064112A (ko) 2017-10-03 2020-06-05 크리티테크, 인크. 암의 치료를 위한 면역치료제의 전신 전달과 조합된 항신생물성 입자의 국소 전달
SG11202003652QA (en) 2017-10-27 2020-05-28 Univ New York Anti-galectin-9 antibodies and uses thereof
IL277402B1 (en) 2018-03-20 2026-04-01 Abraxis Bioscience Llc Methods for treating central nervous system disorders using administration of MTOR inhibitor nanoparticles and albumin
GB201908352D0 (en) * 2019-06-11 2019-07-24 Innovation Ulster Ltd Sonodynamic therapy
JP7703513B2 (ja) * 2019-08-01 2025-07-07 ニューヨーク・ユニバーシティ 抗ガレクチン９抗体と化学療法剤の組合せがん治療
KR20220106758A (ko) 2019-10-28 2022-07-29 아브락시스 바이오사이언스, 엘엘씨 알부민 및 라파마이신의 제약 조성물
US20230085602A1 (en) * 2020-02-04 2023-03-16 Swedish Orphan Biovitrum AB (publ ) Pdac treatment regimen
WO2024186320A1 (en) * 2023-03-09 2024-09-12 Minneamrita Therapeutics Llc Drug combination for treatment of pancreatic cancer
CN117099681B (zh) * 2023-08-28 2024-07-05 南京农业大学 一种利用紫杉醇加倍玉米单倍体的方法

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5997904A (en) 1993-02-22 1999-12-07 American Bioscience, Inc. Total nutrient admixtures as stable multicomponent liquids or dry powders and methods for the preparation thereof
US6749868B1 (en) 1993-02-22 2004-06-15 American Bioscience, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US5439686A (en) 1993-02-22 1995-08-08 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
US6753006B1 (en) 1993-02-22 2004-06-22 American Bioscience, Inc. Paclitaxel-containing formulations
US6537579B1 (en) 1993-02-22 2003-03-25 American Bioscience, Inc. Compositions and methods for administration of pharmacologically active compounds
US20030068362A1 (en) 1993-02-22 2003-04-10 American Bioscience, Inc. Methods and formulations for the delivery of pharmacologically active agents
US5362478A (en) 1993-03-26 1994-11-08 Vivorx Pharmaceuticals, Inc. Magnetic resonance imaging with fluorocarbons encapsulated in a cross-linked polymeric shell
US5650156A (en) 1993-02-22 1997-07-22 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of nutriceuticals and compositions useful therefor
US6528067B1 (en) 1993-02-22 2003-03-04 American Bioscience, Inc. Total nutrient admixtures as stable multicomponent liquids or dry powders and methods for the preparation thereof
JP3746293B2 (ja) 1993-02-22 2006-02-15 アメリカン バイオサイエンス、インコーポレイテッド 生物製剤のインビボ送達の方法とそのための組成物
US6096331A (en) 1993-02-22 2000-08-01 Vivorx Pharmaceuticals, Inc. Methods and compositions useful for administration of chemotherapeutic agents
US5916596A (en) 1993-02-22 1999-06-29 Vivorx Pharmaceuticals, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US6565842B1 (en) 1995-06-07 2003-05-20 American Bioscience, Inc. Crosslinkable polypeptide compositions
US8137684B2 (en) 1996-10-01 2012-03-20 Abraxis Bioscience, Llc Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
ES2435944T3 (es) 1997-06-27 2013-12-26 Abraxis Bioscience, Llc Nuevas formulaciones de agentes farmacológicos, métodos para su preparación y métodos para su uso
US8853260B2 (en) 1997-06-27 2014-10-07 Abraxis Bioscience, Llc Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US20030199425A1 (en) 1997-06-27 2003-10-23 Desai Neil P. Compositions and methods for treatment of hyperplasia
CA2369740A1 (en) 1999-04-22 2000-11-02 American Biosciences, Inc. Long term administration of pharmacologically active agents
CA2371912C (en) 1999-05-21 2010-02-16 American Bioscience, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
ITMI20001107A1 (it) 2000-05-18 2001-11-18 Acs Dobfar Spa Metodo per il trattamento di tumori solici mediante microparticelle di albumina incorporanti paclitaxel
ITMI20020681A1 (it) * 2002-03-29 2003-09-29 Acs Dobfar Spa Procedimento per la produzione di nanoparticelle di paclitaxel ed albumina
EP1585548B1 (en) 2002-12-09 2018-06-27 Abraxis BioScience, LLC Compositions and methods of delivery of pharmacological agents
KR20140148502A (ko) 2002-12-09 2014-12-31 아브락시스 바이오사이언스, 엘엘씨 약리학적 물질의 조성물 및 그 전달방법
US20070166388A1 (en) 2005-02-18 2007-07-19 Desai Neil P Combinations and modes of administration of therapeutic agents and combination therapy
WO2006089290A1 (en) 2005-02-18 2006-08-24 Abraxis Bioscience Inc.. Combinations and modes of administration of therapeutic agents and combination therapy
AU2012201568B2 (en) 2005-02-18 2014-07-31 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
US8735394B2 (en) 2005-02-18 2014-05-27 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
JP2008539265A (ja) * 2005-04-29 2008-11-13 コーザン バイオサイエンシス インコーポレイテッド １７−ａａｇ又は１７−ａｇ又はどちらかのプロドラッグを使用する多発性骨髄腫の治療方法
BRPI0615265A8 (pt) 2005-08-31 2018-03-06 Abraxis Bioscience Llc composições compreendendo agentes farmacêuticos pouco hidrossoluíveis e agentes antimicrobianos
US8034765B2 (en) 2005-08-31 2011-10-11 Abraxis Bioscience, Llc Compositions and methods for preparation of poorly water soluble drugs with increased stability
JP2007297339A (ja) * 2006-04-29 2007-11-15 Torii Yakuhin Kk 癌を治療又は検査するための医薬
BRPI0622006A2 (pt) 2006-08-31 2011-12-20 Abraxis Bioscience Llc usos de proteìna-veìculo e dìmero de colchicina ou tiocolchicina, forma unitária de dosagem, composição farmacêutica e kits
PT2117520T (pt) 2006-12-14 2018-12-04 Abraxis Bioscience Llc Terapia do cancro da mama com base no estado do receptor do hormona com nanoparticulas compreendendo taxane
LT2481402T (lt) 2007-03-07 2018-10-25 Abraxis Bioscience, Llc Nanodalelė, apimanti rapamiciną ir albuminą, kaip priešvėžinį agentą
US20100166869A1 (en) 2007-05-03 2010-07-01 Desai Neil P Methods and compositions for treating pulmonary hypertension
AU2008260447B2 (en) 2007-06-01 2013-10-10 Abraxis Bioscience, Llc Methods and compositions for treating recurrent cancer
KR20150136137A (ko) 2008-04-10 2015-12-04 아브락시스 바이오사이언스, 엘엘씨 소수성 탁산 유도체의 조성물 및 그의 용도
CA2721153C (en) 2008-04-10 2018-10-02 Abraxis Bioscience, Llc Compositions of hydrophobic taxane derivatives and uses thereof
KR101674097B1 (ko) * 2008-04-11 2016-11-08 시애틀 지네틱스, 인크. 췌장, 난소 및 다른 암의 검출 및 치료
NZ593343A (en) 2008-12-11 2013-04-26 Abraxis Bioscience Llc Combination cancer treatment conprising Abraxane and an inflamatory inhibitor
GB0900555D0 (en) 2009-01-14 2009-02-11 Topotarget As New methods
BRPI1008955A2 (pt) 2009-03-13 2015-09-01 Abraxis Bioscience Llc Terapia de combinação com derivados de tiocolchicina.
EP2416650B1 (en) 2009-04-10 2020-02-26 Abraxis BioScience, LLC Nanoparticle formulations and uses therof
CN102460167B (zh) 2009-04-15 2015-07-22 阿布拉科斯生物科学有限公司 不含朊病毒的纳米颗粒组合物和方法
WO2010138839A2 (en) * 2009-05-28 2010-12-02 Abraxis Bioscience, Llc Use of 2 anti-sparc antibodies to predict response to chemotherapy
JP2013503174A (ja) 2009-08-25 2013-01-31 アブラクシス バイオサイエンス， エルエルシー タキサンおよびヘッジホッグ阻害剤のナノ粒子組成物を使用する併用療法
JP2011079788A (ja) * 2009-10-08 2011-04-21 Oita Univ 膵癌に対する選択的膵動脈制癌剤注入療法と全身化学療法との併用療法、およびそれに使用する膵癌治療薬
NZ601324A (en) * 2010-01-05 2014-10-31 Vascular Biogenics Ltd Methods for use of a specific anti-angiogenic adenoviral agent
CN104784121A (zh) 2010-03-26 2015-07-22 阿布拉科斯生物科学有限公司 治疗肝细胞癌的方法
WO2011123393A1 (en) 2010-03-29 2011-10-06 Abraxis Bioscience, Llc Methods of enhancing drug delivery and effectiveness of therapeutic agents
NZ602385A (en) 2010-03-29 2014-08-29 Abraxis Bioscience Llc Methods of treating cancer
EP2552453A2 (en) 2010-03-30 2013-02-06 Clavis Pharma ASA Methods and compositions for treating or ameliorating cancer using gemcitabine-5'-elaidate
JP2013527232A (ja) 2010-06-02 2013-06-27 アブラクシス バイオサイエンス， エルエルシー 膀胱がんの処置方法
KR20130088116A (ko) 2010-06-04 2013-08-07 아브락시스 바이오사이언스, 엘엘씨 췌장암의 치료 방법
MY166014A (en) 2010-06-07 2018-05-21 Abraxis Bioscience Llc Combination therapy methods for treating proliferative diseases
BR112013027674A2 (pt) 2011-04-28 2016-09-06 Abraxis Bioscience Llc "usos de composições de nanopartículas, composições compreendendo as referidas nanopartículas e cateter com uma agulha".
PT2790675T (pt) 2011-12-14 2019-09-23 Abraxis Bioscience Llc Utilização de excipientes poliméricos para a liofilização ou a congelação de partículas
US9149455B2 (en) 2012-11-09 2015-10-06 Abraxis Bioscience, Llc Methods of treating melanoma
US20140186447A1 (en) 2012-12-28 2014-07-03 Abraxis Bioscience, Llc Nanoparticle compositions of albumin and paclitaxel
US9511046B2 (en) 2013-01-11 2016-12-06 Abraxis Bioscience, Llc Methods of treating pancreatic cancer
US20140199405A1 (en) 2013-01-11 2014-07-17 Abraxis Bioscience, Llc Method for treating cancer based on mutation status of k-ras
US20140199404A1 (en) 2013-01-11 2014-07-17 Abraxis Bioscience, Llc Method for treating cancer based on level of a nucleoside transporter
NZ630239A (en) 2013-02-11 2017-08-25 Abraxis Bioscience Llc Methods of treating melanoma
ES2804323T3 (es) 2013-03-12 2021-02-05 Abraxis Bioscience Llc Procedimientos de tratamiento de cáncer de pulmón
AU2014228386B2 (en) 2013-03-13 2018-11-29 Abraxis Bioscience, Llc Methods of treatment of pediatric solid tumor
CA2903548A1 (en) 2013-03-14 2014-09-25 Abraxis Bioscience, Llc Methods of treating bladder cancer
WO2015157120A1 (en) 2014-04-06 2015-10-15 Abraxis Bioscience, Llc Combination therapy comprising nanoparticles of a taxane and albumin with abt-263 in methods for treating cancer
WO2016141365A1 (en) 2015-03-05 2016-09-09 Abraxis Bioscience, Llc Method for treating cancer based on level of glucocorticoid receptor
JP2018527308A (ja) 2015-06-29 2018-09-20 アブラクシス バイオサイエンス， エルエルシー ナノ粒子組成物のためのバイオマーカー
CA2990726A1 (en) 2015-06-29 2017-01-05 Abraxis Bioscience, Llc Methods of treating solid tumors using nanoparticle mtor inhibitor combination therapy
EP3313401B1 (en) 2015-06-29 2021-10-06 Abraxis BioScience, LLC Nanoparticles comprising sirolimus and an albumin for use in treating epithelioid cell tumors
US20170181988A1 (en) 2015-12-23 2017-06-29 Cipla Limited Methods for the treatment of bladder cancer

Also Published As

Publication number Publication date
PL2943192T3 (pl) 2022-01-24
EP2943192A1 (en) 2015-11-18
US9855220B2 (en) 2018-01-02
NZ734971A (en) 2018-12-21
US20180153820A1 (en) 2018-06-07
BR112015016681A8 (pt) 2019-10-22
RS62076B1 (sr) 2021-07-30
SMT202100377T1 (it) 2022-01-10
CA2897589A1 (en) 2014-07-17
CN109793728A (zh) 2019-05-24
BR112015016681A2 (pt) 2017-07-11
IL239739A0 (en) 2015-08-31
ES2878145T3 (es) 2021-11-18
EP2943192B9 (en) 2021-09-29
WO2014110443A1 (en) 2014-07-17
HRP20211062T1 (hr) 2021-12-24
DK2943192T3 (da) 2021-07-05
KR102205710B1 (ko) 2021-01-21
EP2943192B1 (en) 2021-05-12
KR20150103745A (ko) 2015-09-11
CA2897589C (en) 2021-03-02
PT2943192T (pt) 2021-07-16
JP2018087235A (ja) 2018-06-07
US20140199403A1 (en) 2014-07-17
JP6697017B2 (ja) 2020-05-20
EP2943192A4 (en) 2016-06-01
LT2943192T (lt) 2021-08-10
NZ630230A (en) 2017-09-29
US9511046B2 (en) 2016-12-06
HK1216853A1 (zh) 2016-12-09
JP2016505018A (ja) 2016-02-18
CY1124273T1 (el) 2022-11-25
MX2015008898A (es) 2015-10-14
US10328031B2 (en) 2019-06-25
HUE056612T2 (hu) 2022-02-28
CN105025893A (zh) 2015-11-04
JP6342918B2 (ja) 2018-06-13
ZA201504877B (en) 2016-10-26
AU2013203699B2 (en) 2016-09-08
US20170020824A1 (en) 2017-01-26
AU2013203699A1 (en) 2014-10-30
JP2019081790A (ja) 2019-05-30
IL272905A (en) 2020-04-30
SI2943192T1 (sl) 2021-09-30

Similar Documents

Publication Publication Date Title
MX2015008898A (es) Metodos para el tratamiento de cancer pancreatico.
MX2015010312A (es) Metodos para tratamiento del melanoma.
MX389667B (es) Antagonistas de unión al eje pd-1 y taxanos para usarse en el tratamiento de cáncer.
CR20150316A (es) Compuestos y sus métodos de empleo
CL2015002472A1 (es) Como inhibidores de mutant idh-yl-oxazolidin-2-onas 3-pirimidin-4.
MX2016002137A (es) Ciertas entidades quimicas, composiciones y metodos.
MX393818B (es) Terapias de combinación para el tratamiento de cáncer.
SI3331915T1 (sl) Zaviralci kontrolnih točk za uporabo v zdravljenju rakov, ki se prenašajo s krvjo
BR112012030699A2 (pt) métodos para tratar câncer de bexiga
MX2015008888A (es) Metodo para tratar el cancer basado en el nivel de un transportador de nucleosido.
CL2015000897A1 (es) Composición farmacéutica que contiene un portador de oxígeno basado en hemoglobina para el tratamiento de focalización de cáncer y prevención de recurrencia de cáncer.
EP3076972A4 (en) Cancer treatment with combination of plinabulin and taxane
MX2015011899A (es) Metodos para el tratamiento de cáncer y prevención de resistencia a los fármacos para el cáncer.
MX2018003301A (es) Inhibidores de pcna.
CL2015001202A1 (es) Compuestos derivados de oxazolidin-2-ona-pirimidina; composicion y combinacion farmaceutica y uso en el tratamiento del cancer.
IL241823B (en) Preparations containing novyi .c and their uses for the treatment of cancerous tumors
BR112017009265A2 (pt) apilimode para uso no tratamento do câncer colorretal
MX2017012553A (es) Compuestos espirociclicos.
UY34575A (es) Composiciones y métodos para el tratamiento de diabetes y/u obesidad
MX359209B (es) Terapia de combinacion de procaspasa para gliobastoma.
UY34178A (es) Dosificación y administración de anticuerpos anti-erbb3 en combinación con paclitaxel para el tratamiento de cánceres ginecológicos.
MX2020009966A (es) Formas de dosificacion y usos terapeuticos de la l-4-cloro quinurenina.
MX2016015568A (es) Derivados de nucleosidos para el tratamiento del cancer.
EA201591709A1 (ru) 5-бром-индирубины
PH12014502109A1 (en) Methods of treating cancer using aurora kinase inhibitors